



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428      **Phone:** (800) 745-7318

## Oral Antibiotics and Anti-Infectives Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Medication requested

- |   |  |
|---|--|
| <input type="checkbox"/> amoxicillin/clavulanate extended-release   | <input type="checkbox"/> Egaten (triclabendazole)                                      |
| <input type="checkbox"/> Augmentin (amoxicillin/clavulanate 125/31.25 mg/5 mL suspension)                       | <input type="checkbox"/> Lampit (nifurtimox)   |
| <input type="checkbox"/> Baxdela (delafloxacin tablet)  | <input type="checkbox"/> linezolid suspension, tablet                                  |
| <input type="checkbox"/> cefaclor extended-release  | <input type="checkbox"/> mebendazole   |
| <input type="checkbox"/> cefadroxil tablet  | <input type="checkbox"/> metronidazole 375 mg capsule                                  |
| <input type="checkbox"/> cefixime   | <input type="checkbox"/> minocycline extended-release 45 mg, 90 mg, 135 mg tablet      |
| <input type="checkbox"/> cephalixin 333 mg capsule  | <input type="checkbox"/> minocycline tablet  |
| <input type="checkbox"/> cephalixin 750 mg capsule  | <input type="checkbox"/> Minolira (minocycline extended-release 105 mg, 135 mg tablet) |
| <input type="checkbox"/> ciprofloxacin extended-release   | <input type="checkbox"/> moxifloxacin tablet   |
| <input type="checkbox"/> clarithromycin extended-release  | <input type="checkbox"/> nitazoxanide tablet   |
| <input type="checkbox"/> Coartem (artemether/lumefantrine) > 24 units/365 days                                  | <input type="checkbox"/> Nuzyra (omadacycline tablet)                                  |
| <input type="checkbox"/> Difucid (fidaxomicin)  | <input type="checkbox"/> ofloxacin tablet  |
| <input type="checkbox"/> Doryx (doxycycline hyclate delayed-release 120 mg tablet)                              | <input type="checkbox"/> pyrimethamine   |
| <input type="checkbox"/> doxycycline hyclate 75 mg, 150 mg tablet   | <input type="checkbox"/> quinine   |
| <input type="checkbox"/> doxycycline hyclate delayed-release 50 mg, 75 mg, 80 mg, 100 mg, 150 mg, 200 mg tablet | <input type="checkbox"/> Sivextro (tedizolid tablet)                                   |
| <input type="checkbox"/> doxycycline monohydrate 40 mg capsule  | <input type="checkbox"/> Solosec (secnidazole)   |
| <input type="checkbox"/> doxycycline monohydrate 75 mg capsule  | <input type="checkbox"/> tinidazole  |
| <input type="checkbox"/> doxycycline monohydrate 150 mg capsule   | <input type="checkbox"/> Xenleta (lefamulin tablet)                                    |
| <input type="checkbox"/> doxycycline monohydrate 150 mg tablet  | <input type="checkbox"/> Xifaxan (rifaximin 550 mg)                                    |
|   | <input type="checkbox"/> Ximino (minocycline extended-release capsule)                 |

**Dose, frequency, and duration of medication requested** \_\_\_\_\_

**Indication** \_\_\_\_\_

---

**Section I. Please complete for all requests.**

1. Is the member under the care of an Infectious Disease specialist?  Yes  No
2. Please list previous trials for the requested indication including outcomes.\*

Drug \_\_\_\_\_ Outcome \_\_\_\_\_ Dates of use \_\_\_\_\_  
Drug \_\_\_\_\_ Outcome \_\_\_\_\_ Dates of use \_\_\_\_\_  
Drug \_\_\_\_\_ Outcome \_\_\_\_\_ Dates of use \_\_\_\_\_

\*Attach a letter with additional information regarding medication trials as applicable.

---

**Section II. Please complete for all requests for antibiotics.**

1. Please indicate the infecting organism.
- Clostridium difficile  Vancomycin-resistant Enterococcus (VRE)  
 Methicillin-resistant Staphylococcus aureus (MRSA)  Other \_\_\_\_\_
2. Is the infecting organism confirmed or suspected?  Confirmed  Suspected
3. Were cultures and susceptibility testing performed?
- Yes. Please attach a copy of the culture and sensitivity report with submission.  
 No. Please provide clinical rationale why cultures and susceptibility testing were not performed.
- 

---

**Section III. Please also complete for requests for amoxicillin/clavulanate extended-release, cefaclor extended-release, ciprofloxacin extended-release, and clarithromycin extended-release.**

Please describe the medical necessity for the use of an extended-release dosage form over immediate-release formulations of the requested agent. Please describe prior trials and outcomes with the immediate-release formulation and additional antibiotics, if applicable, in Section I above.

---

---

**Section IV. Please also complete for requests for cefadroxil tablet, cephalixin 333 mg and 750 mg capsule, and metronidazole 375 mg.**

Please describe prior trials and outcomes with formulations of the requested antibiotic that are available without PA in Section I above. Please describe medical necessity for the use of the requested antibiotic over alternative strengths that do not require a PA.

---

---

**Section V. Please also complete for requests for doxycycline agents requiring PA.**

Please describe prior trials and outcomes with doxycycline formulations that are available without PA in Section I above. Please provide clinical rationale for the requested formulation.

---

---

**Section VI. Please also complete for requests for cefixime.**

- Is the member completing a course of therapy that was initiated in the hospital?  Yes  No
- If the answer to the above question is no, has the member had a trial with cefdinir or cefpodoxime?
- Yes. Please describe prior trials and outcomes in Section I above.  
 No. Please explain why not. \_\_\_\_\_
- 

---

**Section VII. Please also complete for requests for Xifaxan 550 mg.**

1. For the diagnosis of hepatic encephalopathy, has the member tried lactulose?
- Yes. Please describe prior trials and outcomes in Section I above.  
 No. Please explain why not. \_\_\_\_\_
-

2. For the diagnosis of irritable bowel syndrome with diarrhea, has the member had a trial with three of the following: loperamide, diphenoxylate/atropine, bile acid sequestrant, bismuth subsalicylate, bulk-forming agent, tricyclic antidepressant (TCA)?
- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_

---

**Section VIII. Please also complete for requests for linezolid tablet and Sivextro tablet.**

1. For Sivextro for the diagnosis of VRE, has the member had a trial with linezolid?
- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_
2. For the diagnosis of MRSA, has the member had a trial with clindamycin, doxycycline or minocycline, sulfamethoxazole/trimethoprim, or vancomycin IV?
- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_

---

**Section IX. Please also complete for requests for minocycline extended-release 45 mg, 90 mg, 135 mg tablets, minocycline tablets, Minolira, and Ximino.**

1. For minocycline immediate-release tablet, please describe prior trials and outcomes with minocycline capsules in Section I above. Please describe clinical rationale for the dosage form over immediate-release capsules. \_\_\_\_\_
2. For minocycline extended-release tablet and capsule formulations, has the member had a trial with minocycline capsules and Solodyn?
- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_

---

**Section X. Please also complete for requests for Dificid.**

Has the member had a trial with oral vancomycin?

- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_

---

**Section XI. Please also complete for Augmentin 125/31.25 mg/5 mL suspension requests.**

Please provide clinical rationale for not using 250/62.5 mg/5 mL formulation.

\_\_\_\_\_

---

**Section XII. Please also complete for requests for Baxdela tablet and Nuzyra tablet.**

1. For suspected or confirmed MRSA infections or mixed pathogen infections (including MRSA), has the member had a trial with clindamycin, doxycycline or minocycline, sulfamethoxazole/trimethoprim, or vancomycin IV?
- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_
2. For suspected or confirmed MRSA infections or mixed pathogen infections (including MRSA), has the member had a trial with linezolid?
- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_

---

**Section XIII. Please also complete for requests for moxifloxacin tablet and ofloxacin tablet.**

Has the member had a trial with ciprofloxacin or levofloxacin?

- Yes. Please describe prior trials and outcomes in Section I above.
- No. Please explain why not. \_\_\_\_\_

---

**Section XIV. Please also complete for requests for Coartem > 24 units/365 days.**

Please describe the medical necessity for exceeding the quantity limit.

---

---

**Section XV. Please also complete for requests for Lampit.**

Member's current weight \_\_\_\_\_ Date \_\_\_\_\_

---

---

**Section XVI. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

---

---

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_

NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_

DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_

Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

E-mail address \_\_\_\_\_

Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

\* *Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_